SCHEMBL6414138

SCHEMBL6414138

N/N=C(\c1ccc(O)cc1)c1nc2nonc2nc1NCc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 1/20 0.38
EGFR P00533 3/20 0.38
KDR P35968 1/20 0.38
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
MAPT P10636 3/20 0.36
BLM P54132 2/20 0.36
KDM4E B2RXH2 2/20 0.36
AXL P30530 1/20 0.36
FLT3 P36888 1/20 0.36
MERTK Q12866 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 2/20 0.36
CSNK1D P48730 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414153 1.00 STAT6 (0.38) STAT6EGFRKDRMEN1KMT2A
SCHEMBL6433104 0.90 ALDH1A1 (0.41) MEN1KMT2AMAPTBLMKDM4E
SCHEMBL6433087 0.90 ALDH1A1 (0.41) MEN1KMT2AMAPTBLMKDM4E
SCHEMBL6418374 0.88 EGFR (0.40) EGFRKDRMEN1KMT2AMAPT
SCHEMBL6418383 0.88 EGFR (0.40) EGFRKDRMEN1KMT2AMAPT
SCHEMBL6415738 0.85 EGFR (0.39) STAT6EGFRKDRMEN1KMT2A
SCHEMBL6415718 0.85 EGFR (0.39) STAT6EGFRKDRMEN1KMT2A
SCHEMBL6414661 0.84 MEN1 (0.37) STAT6EGFRKDRMEN1KMT2A
SCHEMBL6414671 0.84 MEN1 (0.37) STAT6EGFRKDRMEN1KMT2A
SCHEMBL6416068 0.83 LDHA (0.46) KMT2AMAPK1GAACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 STAT6 3392/4885EGFR 1083/4885KDR 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.